Navigation Links
Symphony Medical Changes Name to CardioPolymers, Inc.
Date:7/22/2009

LAGUNA HILLS, Calif., July 22 /PRNewswire/ -- Symphony Medical, Inc., a development-stage company focused on novel biopolymer implant therapies to treat cardiac abnormalities, announced today that it has changed the name of the corporation to CardioPolymers, Inc.

CardioPolymers, Inc. Chief Executive Officer Raymond W. Cohen said, "The name change, which is effective immediately, better reflects our focus on employing natural biocompatible polymer implants to treat cardiac patients - specifically, congestive heart failure patients with an enlarged left ventricle."

CardioPolymers is currently sponsoring a human clinical study of its patented flagship technology Algisyl-LVR(R) at world-class centers in Europe, including the German Heart Center in Munich where the first three patients were successfully treated.

Algisyl-LVR is an implantable medical device under clinical development intended to prevent or reverse the progression of congestive heart failure in patients with dilated cardiomyopathy, a condition in which the heart becomes weakened and enlarged, and cannot pump blood efficiently. The procedure involves injecting a proprietary biopolymer directly into strategic locations of the heart's left ventricle wall. As it is injected, the biopolymer thickens and forms firm, gel-like structures that remain in the heart muscle as permanent implants. These implants act to re-shape the heart, reduce the size of the dilated left ventricle and thicken the damaged wall of the heart, thus returning the heart to a healthier form that facilitates improved cardiac function and performance.

About CardioPolymers, Inc.

CardioPolymers, Inc., a Delaware Corporation (formerly known as Symphony Medical) was founded in 2003 and is headquartered in Orange County, California. The Company is privately held and backed by venture investors Johnson & Johnson, Domain Associates, Morgenthaler Ventures, Triathlon Medical Ventures and Fjord Ventures. The development stage company is developing proprietary biotherapeutic products and tools to address the unmet clinical needs of millions of patients suffering from cardiac disorders.

For more information on CardioPolymers, Inc. please visit our website at

www.symphonymed.com

    Contact:  Matt Clawson
              Allen & Caron Inc
              949-474-4300
              matt@allencaron.com


'/>"/>
SOURCE CardioPolymers, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Symphony Managemnt Consulting Hires New Solutions Director
3. Angiotech and Symphony Medical Announce Licensing Agreement
4. Environmental Tectonics Corporation Announces Promotion of Don R. Webber to VP of Sales for their BioMedical Division
5. Regado Biosciences Expands Medical Advisory Board
6. BioMS Medical announces second quarter 2009 results
7. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
8. American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification
9. Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
10. Powerful Image Registration and Recognition Software Unveiled for Medical, Satellite, and Defense Imaging Industries
11. IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
Breaking Biology Technology:
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
Breaking Biology News(10 mins):